Fc-Fusion Coagulation Factor Assay for Hemophilia Monitoring
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hemophilia A and B are invasive, inconvenient, and require frequent administration due to the short half-life of recombinant Factor VIII and IX proteins, and existing coagulation assays are complex and impractical for home use, limiting monitoring and management of bleeding disorders.
Innovation Solution
A composition comprising an activated coagulation factor and a phospholipid mixture dried onto a solid substrate for measuring coagulation factor activity, allowing for point-of-care testing of clotting time, enabling more tolerable and effective treatment of hemophilia and improved monitoring of bleeding disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If recombinant Factor VIII and IX proteins are used to treat hemophilia, then treatment effectiveness is improved, but the frequency of administration increases due to short half-life
Solution Approach 1:
The patent modifies the pharmacokinetic parameters of Factor VIII and IX by fusing them to the Fc portion of immunoglobulins. This parameter change extends the half-life from hours to days, reducing administration frequency from multiple times per week to once or twice per week, while maintaining treatment effectiveness.
Solution Approach 2:
The patent creates composite protein structures by fusing coagulation factors (Factor VIII or IX) to the Fc portion of human immunoglobulins. This composite structure combines the hemostatic activity of the coagulation factor with the extended half-life properties of the Fc region, achieving both treatment effectiveness and reduced administration frequency.
2Manufacturing precision
If plasma-derived Factor IX is purified from blood, then treatment purity is improved, but the difficulty of purification increases due to low concentration and need to remove infectious agents
Solution Approach 1:
The patent uses recombinant DNA technology to copy and produce Factor IX in bacterial or cell cultures, eliminating the need for complex purification from plasma. This allows for consistent purity and eliminates the risks associated with plasma-derived products, including infectious agent removal.
Solution Approach 2:
The patent replaces the mechanical and chemical purification processes required to extract Factor IX from plasma with recombinant DNA technology. This substitution eliminates the need for complex chromatography and filtration steps, reducing purification difficulty while maintaining high purity.
3Measurement precision
If conventional coagulation assays are used to monitor Factor levels, then measurement accuracy is improved, but the complexity and impracticality for home use increases
Solution Approach 1:
The patent segments the coagulation assay into a point-of-care format with simplified reagents and procedures. By dividing the complex laboratory assay into manageable components (activated coagulation factor, phospholipid mixture, substrate), it enables accurate Factor VIII and IX level measurement at home or in clinics without requiring complex equipment.
Solution Approach 2:
The patent employs disposable test strips and pre-prepared reagent kits that simplify the assay process. These single-use components eliminate the need for complex, expensive laboratory equipment, making accurate coagulation monitoring accessible to patients at home while maintaining measurement precision.
4Reliability
If frequent intravenous administration is used to maintain therapeutic levels, then treatment reliability is improved, but patient convenience and tolerance deteriorates
Solution Approach 1:
The patent changes the pharmacokinetic parameters of the coagulation factors through Fc fusion, extending half-life from hours to days. This parameter change maintains therapeutic levels for longer periods, reducing administration frequency from multiple times per week to once or twice per week, thereby improving patient convenience while maintaining treatment reliability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The solution provides a practical and effective method for measuring coagulation factor activity and clotting time at the point of care, optimizing treatment for hemophilia patients and improving the management of bleeding disorders by reducing the frequency of invasive procedures and enhancing patient monitoring.
Implementation Method 1
measuring coagulation factor activity and clotting time
Data Source
AI summary
The present disclosure provides methods and compositions for diagnosing and treating subject having a bleeding disorder. The disclosed methods comprise contacting a sample, e.g., a blood or plasma sample obtained from the patient, with an activation mixture comprising an activated coagulation factor and a phospholipid mixture, wherein the activation mixture is dried onto a solid substrate. Also provided is a global hemostasis test based on the integration of clotting time (Ct) and pharmacokinetics data. The methods and compositions presented can be applied to point-of-care diagnostic systems.